AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal
Lund May, 16 2024 – AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the the findings of our recent study published in the Multiple Sclerosis and Related Disorders journal. The research sheds light on the importance of understanding the interaction between a drug called natalizumab and a protein in the body called IgG4 for patients undergoing this treatment."Our study not only provides valuable insights into the effectiveness of natalizumab treatment for MS patients but also serves as proof of the effectiveness of our monitoring technology,” said Marco